Biocon Biologics’ biosimilar for psoriasis and arthritis recommended for approval in Europe

 16-Dec-2024

Jamsetji Tata awarded to Kiran Mazumdar-Shaw

 15-Dec-2024

Biocon Biologics recognized as Asia IP Elite for 2024 by Intellectual Asset Management

 11-Dec-2024

Biocon opens Experience Center at its 46th Founder’s Day

 02-Dec-2024

Biocon Biologics gets US nod to launch Stelara biosimilar

 01-Dec-2024

There is need for tech-driven approaches to biology: Kiran Mazumdar-Shaw

 20-Nov-2024

Bioengineering is really the way we have to move forward: Mazumdar-Shaw

 19-Nov-2024

‘We will continue to explore options to further reduce debt in the near term’

 12-Nov-2024

Will launch 3 biosimilars globally in 2-3 years: Biocon Biologics CEO & MD

 05-Nov-2024

Biocon Biologics Confident Of Tackling Pricing Pressures, Ready To Compete

 05-Nov-2024

A Conversation with Joshua Salsi, Head of North America, Biocon Biologics

 04-Nov-2024

Biocon projects accelerated growth for H2 FY25 fuelled by product launches, increased volume

 04-Nov-2024

Biocon and Dr. Reddy’s Lab make it to ‘Science’ magazine’s Top Employers List again

 29-Oct-2024

Biocon Biologics Announces Results of Aflibercept Switching Study at American Academy of Ophthalmology Annual Meeting

 24-Oct-2024

Kiran Mazumdar-Shaw Honored with Doctor of Science Degree by Concordia University for Pioneering Contributions to Biotechnology

 18-Oct-2024

Need to strengthen national policies to increase access and adoption of biosimilars, reveals new report

 08-Oct-2024

‘Quiet Giant’ Biocon Sets Out Vision For Biosimilars

 07-Oct-2024

With refinancing done, focus will now be on debt reduction: Biocon Biologics CFO

 04-Oct-2024

Biocon Biologics Adalimumab and Ustekinumab Biosimilars Meet Phase 3 Trial Objectives

 26-Sep-2024

Biology opens up new frontiers in medicine to cure genetic diseases: Kiran Mazumdar Shaw

 14-Sep-2024

Biocon is targeting to be a gender parity company by 2030, says Kiran Mazumdar Shaw

 31-Aug-2024

Biocon Biologics Inks Pact with JJ and Janssen Arms to Market ‘Bmab’ in Europe and Japan

 29-Aug-2024

Kiran Mazumdar-Shaw: Spearheading pharma innovation

 26-Aug-2024

Local clinical trial waiver will accelerate access to lifesaving drugs: Kiran Mazumdar-Shaw

 21-Aug-2024

May look to bring Liraglutide via clinical trial waiver: Mazumdar-Shaw

 11-Aug-2024

Biocon plans to expand margins to 25%, led by new products and markets: Group CEO Peter Bains

 9-Aug-2024

Biocon Facility Gets Inspection Report From US FDA, Voluntary Action Indicated

 5-Aug-2024

Biocon gets US FDA report after Vizag facility scan; no more regulatory action needed

 5-Aug-2024

Excited about gain in market share in US, says Biocon chief Kiran Mazumdar Shaw

 25-June-2024

EMA approves Biocon Biologics’ new monoclonal antibodies facility, renews GMP certifications for India and Malaysia sites

 24-June-2024

Biocon Biologics gets EMA nod to manufacture biosimilar Bevacizumab at its new facility in Bengaluru

 24-June-2024

Biocon inks licensing, supply pact with South Korea’s Handok for chronic weight management product

 20-June-2024

Biocon receives US FDA approval for antifungal drug micafungin

 04-June-2024

Aim is to be among top three biosimilars players globally: Biocon Biologics CEO Shreehas Tambe

 27-May-2024

Biocon bets on weight-loss drugs as major growth engine for the business

 21-May-2024

Acceleration of biosimilar business, debt reduction to be key priorties in FY25: Biocon Chief

 18-May-2024

Biocon’s Biosimilar Business Set For Strong Growth: CEO Shreehas Tambe

 18-May-2024

Biocon Group CEO sees enormous opportunities in weight loss drugs market

 17-May-2024

Biocon inks licensing pact with Biomm for diabetes management drug Semaglutide in Brazil

 17-Apr-2024

Biocon becomes the first generics company to get a diabetes drug approval in the UK

 28-Mar-2024

Biocon Biologics Signs 10-Year Deal With Eris Lifesciences To Expand Patient Access

 14-Mar-2024

Biocon Biologics: US Biosimilars Are A Marathon, Not A Sprint

 13-Mar-2024

Biocon Biologics secures Canada market entry date for YESAFILI

 04-Mar-2024

Biocon Biologics Secures US Entry Date For Bmab 1200, A Stelara Biosimilar

 01-Mar-2024

Biocon included in S&P Global Sustainability Yearbook 2024

 20-Feb-2024

Biocon Biologics focusing on market share gains of biosimilars in key markets

 13-Feb-2024

Biocon Biologics inks pact with Sandoz for sale of 2 biosimilar products in Australia

 09-Feb-2024

Biocon Q3FY24 results: Net profit at Rs 660 crore, revenue up 50%

 08-Feb-2024

Biocon gets USFDA approval to market generic anti-cancer medication

 O6-Feb-2024

Budget ’24 | A vision of ‘Viksit Bharat’, driven by inclusion and innovation: Kiran Mazumdar Shaw

 02-Feb-2024

Biocon Group concludes month-long sustainability initiatives with ‘Nature Positive’ campaign

 O3-July-2023

Kiran Mazumdar-Shaw says Biocon in a position to pursue high growth trajectory

17-Mar-2023

Kotak’s alternative investment fund pumps in ₹1,070 cr in Biocon

22-Fab-2023

Biocon Biologics prioritises integration of Viatris assets

16-Feb-2023

Biocon Foundation wins ‘IHW Gold Award for Diseases Screening Initiative of the Year’ for 2022

24-Jan-2023

Biocon Biologics recognised for great managers

 23-Dec-2022

Biocon Biologics appoints Shreehas Tambe as MD & CEO

 05-Dec-2022

‘Science 2022 Top Employer List’ recognises two Indian pharma companies

 02-Nov-2022

Biocon in pact with Japan’s Yoshindo to commercialise two biosimilar assets

17-Oct-2022

Biocon Foundation receives the ‘Mahatma Award 2022 For Excellence in Social Good’

 08-Oct-2022

Never let gender come in the way of your ambitions, dream big: Kiran Mazumdar-Shaw at Yuva Unstoppable event

03-Oct-2022

Biocon’s growth drivers are in place: 5 reasons it is this week’s stock pick

03-Oct-2022

Want to be remembered more than just woman of science: Kiran Mazumdar-Shaw

25-Sep-2022

Mazumdar-Shaw awarded H.K. Firodia Lifetime Achievement Award 2022

25-Sep-2022

Biocon CEO says no intention to sell further stake in Syngene

 07-Sep-2022

Biocon Biologics’ Malaysian unit enters Malaysia Book of Record

 05-Aug-2022

Biocon Biologics’ antibody drug unit in Bengaluru gets EU GMP certificate

 06-July-2022

Biocon Biologics receives EU GMP certification for its new biologics manufacturing facility in Bengaluru

 05-July-2022

Biocon Biologics expects big gains from integration of Viatris business, SII deal

 09-June-2022

Expect regulatory nods for deal with Serum and Viatris to come by H2: Kiran Mazumdar-Shaw, chairperson, Biocon and Biocon Biologics

04-May-2022

Biocon Biologics may close $3.34 billion Viatris deal in Q1

02-May-2022

Eyeing over 15% market share in US for insulin Glargine: Shreehas Tambe

30-April-2022

Biocon Biologics expects R&D expenses to hover between 10-15% in the next financial year

29-April-2022

Biocon arm to buy US company Biosimilar biz for $3.34 billion

01-Mar-2022

Biocon Biologics acquires Viatris for $3.33 billion

01-Mar-2022

Biocon Biologics acquires Viatris’ biosimilars business in $3.3 bn deal

28-Feb-2022

R&D expenditure will rise in the coming quarters: Biocon Biologics MD

25-Jan-2022

Insulins access program for young expanded in Dec quarter: Biocon Biologics MD

24-Jan-2022

Biocon Biologics set to reap biosimilar insulin glargine opportunity in US

22-Jan-2022

The Medicine Box: Kiran Mazumdar-Shaw on biosimilar interchangeable status for Biocon’s diabetes drug

25-Nov-2021

Biocon Biologics, Viatris confirm offering steep savings on long-acting insulin through Walgreens Prescription Savings Club

19-Nov-2021

Walgreens to sell Biocon’s insulin Semglee in the U.S.

19-Nov-2021

Biocon Biologics, Viatris launch interchangeable insulin biosimilar for US

 16-Nov-2021

Biocon starts campaign to treat diabetic children, train healthcare workers

 15-Nov-2021

Access to diabetes care: If not now, then when?

 14-Nov-2021

Biocon Rating: Hold – Vaccines to complement biosimilar portfolio

 20-Sep-2021

Biocon Biologics, Serum Institute Life Sciences announce strategic alliance

 20-Sep-2021

Biocon jumps into vaccines through $4.9bn Serum Institute pact

 20-Sep-2021

Can Serum deal provide a booster dose to Biocon’s target price?

 20-Sep-2021

Interchangeable insulin to help us compete with big insulin makers: Kiran Mazumdar-Shaw

 29-Aug-2021

Vaccines alone will not protect and make the world safer: Biocon chief

 30-Jul-2021

India must use, share Covid data transparently: Kiran Mazumdar-Shaw

 26-Jul-2021

Biocon partners Adagio for licence to make Covid-19 antibody cocktail

 26-Jul-2021

Biocon eyes market share expansion in developed, emerging markets: Kiran Mazumdar-Shaw

 23-Jul-2021

Biocon Q4 profit more than doubles to Rs 254 crore

 29-Apr-2021

Shreehas Tambe named Deputy CEO of Biocon Biologics

 02-Mar-2021

Biocon Biologics, Viatris get CHMP nod for Abevmy

 02-Mar-2021

Biocon Biologics to partner with International Diabetes Federation

 16-Feb-2021

Biocon arm, CHAI in pact on affordable cancer therapies

 04-Feb-2021

Expect Accelerated Growth from Next Fiscal, Says Kiran Mazumdar-Shaw

 25-Jan-2021

Biocon says may have to delay biologics biz IPO

 25-Jan-2020

PANDEMIC PAIN Biocon Chairperson Kiran Mazumdar-Shaw says the Covid impact on business across the value chain has been larger than expected p2

 25-Jan-2020

Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs

08-Nov-2020

India-based company brings affordable insulin to 2 PH towns

23-Oct-2020

Will Biocon’s COVID-19 anti-inflammatory succeed where IL-6 blockers have failed?

 01-Aug-2020

India’s Biocon secures approval to use drug on coronavirus patients

 11-July-2020

Biosimilar drugs can help us reach $1 billion target soon

16-Jun-2020

Kiran Mazumdar-Shaw named EY World Entrepreneur of 2020

 06-Jun-2020

Covid provides larger opportunity to shape the biosimilar landscape

 19-May-2020

Will invest Rs2,000 crore in small molecules in 3-4 years

 16-May-2020

Biocon wins patent case against Sanofi

 12-Mar-2020

Biocon’s cancer biosimilar gets US FDA acceptance for review

 10-Mar-2020

Biocon chief is EY entrepreneur for 2019

 22-Feb-2020

Biocon Biologics Eyes $200M. Plans IPO in 2 Yrs: Mazumdar-Shaw

 27-Jan-2020

Biocon Q3 PBT up 9%

 24-Jan-2020

Biocon optimistic about hitting $1 billion in revenue by FY22 on back of new launches

 08-Jan-2020

Biocon, partner Mylan launch oncology biosimilar trastuzumab in US

11-Dec-2019

USFDA nod to Biocon’s new Bengaluru unit

28-Nov-2019

Biocon, Mylan get nod for pegfilgrastim drug

28-Nov-2019

Indian company makes it to top 10 best employers in biotech category

30-Oct-2019

Insulin at ₹7 will be a gamechanger for us

26-Oct-2019

Life-enabling product like insulin should be made affordable: Shaw

28-Sep-2019

Biocon plans to halve insulin prices

27-Sep-2019

Biocon sets $1 billion target for biologics business

25-Oct-2019

Biocon subsidiary acquires Pfizer’s R&D facility in Chennai

25-Sep-2019

Blueprint for a Healthy India

25-Sep-2019

Ramp-up of biosimilar portfolio to boost Biocon

22-Aug-2019

Our aim is to be a global leader in biosimilars biz: Biocon Biologics CEO

 30-Jul-2019

Biocon’s net rises 86%, revenue 25%

 26-Jul-2019

Biocon net profit grows 72%

 25-Jul-2019

Biosimilars, research key drivers for Biocon

 18-Jun-2019

Trastuzumab’s US launch will be a big opportunity for Biocon-Mylan: Shaw

 18-Jun-2019

Biocon’s Bengaluru biologics units get European agency nod

 15-Jun-2019

The First Lady of Biotech

 08-Jun-2019

Biocon, Mylan to present data for Ogivri at ASCO meeting

 30-May-2019

Canada clears Mylan & Biocon’s Biosimilar

 23-May-2019

Biologics to boost Biocon business, say analyst

 20-May-2019

Biocon drug gets commercial rights to global markets

 09-May-2019

Biosimilars to help Biocon hit $1bn revenue in FY20

 30-Apr-2019

Biologics, research services the golden goose for Biocon

 27-Apr-2019

Biocon Q4 net profit up 64% to ₹213.7 crore

 26-Apr-2019

Kiran Mazumdar-Shaw conferred with honorary doctorate from Deakin University, Australia

 18-Apr-2019

Violence,EVM glitches, missing names:Rocky start to election

 12-Apr-2019

Research must be promoted in colleges

 08-Apr-2019

ET Prime celebrates Women’s Excellence in Business & Innovation

 05-Apr-2019

Breakthrough innovation is taking place but we’re not leveraging it

 05-Apr-2019

Kiran Mazumdar-Shaw conferred with Honorary Doctorate

 04-Apr-2019

Biocon Biologics India appoints Dr. Christiane Hamacher as CEO

 01-Apr-2019

Biocon chief stresses on gender equality

 29-Mar-2019

Kiran back as Infy’s independent director

 19-Mar-2019

Govt Should Scale Up Philanthropic Capital

 18-Mar-2019

Cost of select insulin increases up to 20%

 15-Mar-2019

Role of Indian women in Science & Technology

 12-Mar-2019

The growing share of biosimilars revenue is doing wonders for our business

 11-Mar-2019

Biosimilars offer a huge opportunity for Biocon

 08-Mar-2019

Future jobs will be different: Shaw

 07-Mar-2019

Pharma specialist new CEO of Biocon Biologics

 03-Mar-2019

Hamacher is CEO of Biocon Biologics

 02-Mar-2019

In bid to curb profiteering, govt caps margins of 42 cancer drugs

 28-Feb-2019

Shortage of women for leadership roles

 23-Feb-2019

Biocon’s revenue up 43%; Net profit up 136%

 18-Feb-2019

Biocon’s Trastuzumab receives approvals in EU

 13-Feb-2019

Kiran Mazumdar-Shaw elected member of US-based NAE

 09-Feb-2019

Socio-Economic Issues Focus Area of Budget 2019

 04-Feb-2019

Budget Quotes

 02-Feb-2019

Biocon, Mylan announce positive CHMP opinion for Fulphila

 01-Feb-2019

Why Quitting Should Never Be An Option

 31-Jan-2019

Stock Reccos

 29-Jan-2019

Biosimilars make Biocon stand apart

 28-Jan-2019

Biocon Dec quarter net zooms over two-fold to ₹217 Cr

 25-Jan-2019

Top-ranked Karnataka doubles down on skill development

 20-Jan-2019

Biocon focus may shift to non-insulins

 16-Jan-2019

A Briefcase and A Baby

 13-Jan-2019

Kiran Mazumdar-Shaw gets second term as Infosys’ Lead Independent Director

 12-Jan-2019

For India’s healthy billion

 07-Jan-2019